Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis
Open Access
- 13 July 2009
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hepatology
- Vol. 50 (5), 1421-1430
- https://doi.org/10.1002/hep.23167
Abstract
Nonalcoholic fatty liver disease (NAFLD) is a potentially progressive liver disease that culminates in cirrhosis. Cirrhosis occurs more often in individuals with nonalcoholic steatohepatitis (NASH) than in those with steatosis (nonalcoholic fatty liver [NAFL]). The difference between NAFL and NASH is the extent of hepatocyte apoptosis, which is more extensive in NASH. Because phagocytosis of apoptotic cells activates hepatic stellate cells (HSCs), we examined the hypothesis that a pan-caspase inhibitor, VX-166, would reduce progression of fibrosis in a mouse model of NASH. Male db/db mice were fed methionine/choline-deficient (MCD) diets to induce NASH and liver fibrosis. Mice were gavaged once daily with either the pan-caspase inhibitor VX-166 (6 mg/kg/d; Vertex, Abingdon, UK) or vehicle only and sacrificed at 4 or 8 weeks. Treatment with an MCD diet increased alanine aminotransferase (ALT), caspase-3 activity, terminal deoxynucleotidyl transferase–mediated dUTP nick-end labeling (TUNEL)-positive cells, NASH, and fibrosis. Treatment of MCD-fed mice with VX-166 decreased active caspase-3, TUNEL-positive cells, and triglyceride content (P < 0.05). However, ALT levels were similar in VX-166–treated mice and vehicle-treated controls. Histological findings also confirmed that both groups had comparable liver injury (NAFLD activity score ≥6). Nevertheless, VX-166–treated MCD-fed mice demonstrated decreased α-smooth muscle actin expression (4 weeks, P < 0.05; 8 weeks, P < 0.005) and had reduced hepatic levels of collagen 1α1 messenger RNA (8 weeks, P < 0.05). Hydroxyproline content and Sirius red staining of VX-166–treated livers confirmed decreases in fibrosis. Conclusion: Inhibiting hepatic apoptosis suppresses the development of fibrosis in mice with NASH. Beneficial effects on liver fibrosis were associated with reductions in hepatic steatosis, but occurred without obvious improvement in liver injury. These findings are consistent with evidence that apoptosis triggers HSC activation and liver fibrosis and suggest that caspase inhibitors may be useful as an antifibrotic NASH therapy. (HEPATOLOGY 2009.)This publication has 23 references indexed in Scilit:
- Hepatic Lipid Partitioning and Liver Damage in Nonalcoholic Fatty Liver Disease: ROLE OF STEAROYL-CoA DESATURASEPublished by Elsevier BV ,2009
- Definition and natural history of metabolic steatosis: clinical aspects of NAFLD, NASH and cirrhosisDiabetes & Metabolism, 2008
- Apoptosis-induced compensatory proliferation. The Cell is dead. Long live the Cell!Trends in Cell Biology, 2008
- Sonic hedgehog is an autocrine viability factor for myofibroblastic hepatic stellate cellsJournal of Hepatology, 2008
- Polyunsaturated fat in the methionine-choline-deficient diet influences hepatic inflammation but not hepatocellular injuryJournal of Lipid Research, 2007
- Sustained activation of Rac1 in hepatic stellate cells promotes liver injury and fibrosis in miceHepatology, 2006
- Design and validation of a histological scoring system for nonalcoholic fatty liver diseaseHepatology, 2005
- Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontinAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2004
- The Caspase Inhibitor IDN-6556 Attenuates Hepatic Injury and Fibrosis in the Bile Duct Ligated MouseThe Journal of pharmacology and experimental therapeutics, 2003
- Mitochondrial proteins that regulate apoptosis and necrosis are induced in mouse fatty liverHepatology, 1999